Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins

  • Tae Woo Kim
  • , Chien Fu Hung
  • , Morris Ling
  • , Jeremy Juang
  • , Liangmei He
  • , J. Marie Hardwick
  • , Sharad Kumar
  • , T. C. Wu*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

169 Citations (Scopus)

Abstract

Intradermal vaccination by gene gun efficiently delivers DNA vaccines into DCs of the skin, resulting in the activation and priming of antigen-specific T cells in vivo. DCs, however, have a limited life span, hindering their long-term ability to prime antigen-specific T cells. We reason that a strategy that prolongs the survival of DNA-transduced DCs will enhance priming of antigen-specific T cells and DNA vaccine potency. Here we show that codelivery of DNA encoding inhibitors of apoptosis (BCL-xL, BCL-2, XIAP, dominant negative caspase-9, or dominant negative caspase-8) with DNA encoding model antigens prolongs the survival of transduced DCs. More importantly, vaccinated mice exhibited significant enhancement in antigen-specific CD8+ T cell immune responses, resulting in a potent antitumor effect against antigen-expressing tumors. Among these antiapoptotic factors, BCL-xL demonstrated the greatest enhancement in antigen-specific immune responses and anti-tumor effects. Thus, coadministration of DNA vaccines with DNA encoding antiapoptotic proteins represents an innovative approach to enhance DNA vaccine potency.

Original languageEnglish
Pages (from-to)109-117
Number of pages9
JournalJournal of Clinical Investigation
Volume112
Issue number1
DOIs
Publication statusPublished - 2003 Jul
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins'. Together they form a unique fingerprint.

Cite this